Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients
Authors:
- Giuseppe ManciaGiuseppe Mancia
- Helmut SchumacherHSHelmut Schumacher
- Michael BöhmMBMichael Böhm
- Josep RedonJRJosep Redon
- Roland E. SchmiederRSRoland E. Schmieder
- Paolo VerdecchiaPVPaolo Verdecchia
- Peter SleightPSPeter Sleight
- Koon TeoKTKoon Teo
- Salim YusufSYSalim Yusuf
- 1 November 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 70 (5) , 938-948
Abstract
In 28 790 patients recruited for the ONTARGET (Ongoing Treatment Alone and in Combination With Ramipril Global End Point Trials) and TRANSCEND (Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease) trials, we investigated the prognostic value for cardiovascular events (primary outcome) of (1)on-treatment visit-to-visit systolic blood pressure (SBP) variability versus mean SBP and (2) the 2 measures together. SBP variability was measured by the coefficient of variation (CV) of mean SBP to which it was unrelated. Confounders such as variable time and number of visits from which to calculate SBP-CV were avoided by using the same number of visits at identical times in all patients. The covariate-adjusted risk of the primary outcome (Cox models) increased as SBP-CV or mean on-treatment quintile SBP increased, but only for mean on-treatment SBP, the relationship achieved statistical significance: global test for trend, P =0.12 versus P P <0.0001; hazard ratio for combined fifth versus first quintile, 1.42 (1.20–1.68) compared with 1.13 (1.01–1.27) for SBP-CV and 1.24 (1.11–1.40) for mean SBP. Thus, in the present study, on-treatment mean SBP provided an overall better prediction of cardiovascular risk than visit-to-visit SBP-CV. Prediction improved by their combined use, which may thus offer a more precise estimate of the protective effect of treatment. Clinical Trial Registration—: URL: http//www.clinicaltrial.gov . Unique identifier: NCT153.101.Keywords
This publication has 47 references indexed in Scilit:
- Long-Term and Ultra Long–Term Blood Pressure Variability During Follow-Up and Mortality in 14 522 Patients With HypertensionHypertension, 2013
- Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)PLOS ONE, 2012
- Within-Subject Blood Pressure Level—Not Variability—Predicts Fatal and Nonfatal Outcomes in a General PopulationHypertension, 2012
- Short- and Long-Term Blood Pressure VariabilityHypertension, 2012
- Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients With High-Risk Systemic HypertensionThe American Journal of Cardiology, 2012
- Better compliance to antihypertensive medications reduces cardiovascular riskJournal Of Hypertension, 2011
- The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General PopulationHypertension, 2011
- Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertensionThe Lancet, 2010
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Pulse Pressure and Mortality from Cerebrovascular Diseases in Type 2 Diabetic Patients: The Verona Diabetes StudyCerebrovascular Diseases, 2006